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ApoAI-containing lipoproteins, which have been reported in relation with the development of ischemic 
diseases, have never been studied in obese subjects that have any other factor affecting the 
lipoproteins metabolism. Control and obese women groups were constituted on the basis of the body 
weight: less than 110% and more than 125% of the ideal body weight, respectively. Different lipid and 
lipoprotein parameters, including the two apoAI-containing lipoproteins species, were quantified. 
Compared to control group, obese group exhibited a higher levels of plasma triglycerides, high density 
lipoprotein-triglycerides (HDL-TG) and lipoproteins with both apo AI and apo AII (LpAI:AII) but a lower 
values of plasma-apoAI percentage associated with LpAI particles (P < 0.05). The other studied 
parameters, including the distribution of apoAI and LpAI between HDL and non-HDL fractions, were 
similar in the two subject groups. In our obese subjects, plasma TG appear to be the more determinant 
for the atherosclerosis risk as suggested by their strong positive and negative correlation with LpAI:AII 
(P < 0.001) and with LpAI/LpAI:AII, respectively. The profile of apoAI-containing lipoproteins appears to 
be more sensitive to obesity effect than traditional lipid and lipoprotein parameters. The nature of its 
alteration could explain, at least in part, the association of obesity with high atherosclerosis risk.     
 





The role of lipids in the pathogenesis
 
of heart disease has 
now been firmly established. In particular, the positive 
relation of plasma cholesterol (Chol), triglycerides (TG), 
apo B, low density lipoprotein (LDL)-Chol and the 
negative relation of high density lipoprotein (HDL)-Chol 
and apoAI with the development of this disease have 
been known for a long time (Barter and Rye, 1996; 
Brewer et al., 2004; Vinik, 2005; Paul and Baudin, 2009). 
More recently, other lipoprotein parameters have been 
proposed as atherosclerosis markers. Among these para-
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studied. These lipoproteins are often distinguished in two 
particle   populations:  particles  with  apo AI  and  apoAII 
(LpAI:AII) and particles with apoAI but without apo AII 
(LpAI)
 
(Cheung et al., 1986; Koren et al., 1987; Cheung 
and Wolf, 1989; Barkia, 1990; Barkia et al., 1991). These 
lipoprotein populations were shown to be metabolically 
and functionally different (Fielding and Fielding, 1981; 
Cheung et al., 1986; Barkia et al., 1991). While the rise of 
atherosclerosis has being observed to be positively 
associated with the LpAI:AII concentration, it was nega-
tively linked to the LpAI level (Puchois et al., 1987; 
Asztalos et al., 2000; Nowicka and Jarosz, 2001). 
Moreover, experimental studies reported that, among the 
two apoAI-containing lipoproteins, only LpAI was able to 
trigger the cellular cholesterol efflux (Fielding and 
Fielding, 1981; Barkia et al., 1991). The magnitude of the 
last one was diminished by the co-presence of LpAI: AII 
(Barkia et al., 1991). Consequently, LpAI was considered 
to be an anti-atherogenic particle, while an antagonist 





appear to be decisive factors in the development of the 
atherosclerosis process. So, their quantification, 
particularly in physiopathology associated with an 
elevated atherosclerosis risk, could re-inforce the 
prediction of the risk of cardiovascular disease (CVD). 
Obesity, which concerns a very large population (Kosti 
and Panagiotakos, 2006; Lazarou et al., 2008), is a 
physiopathology condition known for its association with 
increased atherosclerosis risk (Nguyen et al., 2010) 
which could be explained in terms of the co-presence of 
several risk factors (Marinou et al., 2010). In particular, it 
is well established that obesity is strongly associated with 
quantitative and qualitative alterations in plasma lipids 
(Bertière et al.,1988; Kissebah et al., 1989; Pascot et al., 
2001; Ho et al., 2002; Bamba and Rader, 2007; Franssen 
et al., 2008; Korsten-Reck et al., 2008; Chan et al., 2009 ; 
Mori et al., 2009; Taha et al., 2009). These alterations 
classically included an elevation of triglycerides, a low 
HDL-Chol and an excess of small dense LDL fractions. 
We have no information concerning the profile of 
apoAI-containing lipoproteins. The investigation of the 
impact of obesity on this profile is the principal objective 
of our study. 
 
 




On the basis of the body weight excess, two volunteer groups were 
constituted. One control group was formed by 36 women having a 
body weight less than 110% of ideal body weight and one obese 
group was formed by 33 women having a body weight higher than 
125% of ideal body weight. The ideal weights of persons were 
determined by LORENTZ formula and the weight excess was 
calculated as follows [(real weight - ideal weight) / real weight] x100. 
In the order to avoid the sex and hormonal influence, all subjects 
were premenopausal women. Also, all recruited subjects have the 
same ethnic group and socioeconomic origins. They were aged 
between 24 and 40 years. They were not suffering from any known 
pathologies (diabetes, hepatic and kidney disease...), not using oral 
contraceptives or any other medications and they were not on a 
special diet. Except for three subjects (two obese subjects and one 
control) who smoked fifteen to twenty cigarettes daily, the tobacco 
use in others subjects was inexistent or very low (less than of 4 




Treatment of specimen samples 
 
After an overnight fast, blood was collected on sodium azide (2 
µg/ml), gentamycin (5 µg/ml) and disodium ethylene diaminet-
etraacetic acid (0.01 mM). Plasma was rapidly prepared by blood 
centrifugation at 6 - 8°C for 15 min at 3000 rpm. One ml of plasma 
was used for preparation of the HDL fraction. 
The glucose assay was immediate, while other parameters were 
quantified in the two following days. During the 48 h, samples were 
kept at 4°C. Chol, TG, phospholipids (PL), LpAI, apoAI, apoAII and 
apoB were quantified in the plasma (p-Chol, p-TG and p-PL, p-
LpAI, p-apoAI, p-apoAII and p-apoB) whereas only Chol, TG, LpAI 
and apoAI were assayed in the HDL fraction (HDL-Chol, HDL-TG 
HDL-LpAI and HDL-apoAI). 






The level of glucose in the plasma  was  measured  by  the  glucose  
oxidase method (glucose Analyser2, Beckman, USA). The HDL 
fraction was represented by the supernatant liquid obtained after 
precipitation of the plasma apoB-containing lipoproteins with phosp-
hotungstic acid (Biomerieux, France), followed by centrifugation at 
2500 rpm for 15 min. The non-existence of apoB in the supernatant 
was confirmed by electro-immunoassay using plates ready 
containing antibodies anti-apoB. PL (in the plasma) TG and Chol (in 
the plasma and in the HDL fraction) were quantified by enzymatic 
assays employing commercial kits (SERA-PAK for cholesterol and 
triglycerides; BIO-Merieux for phospholipids). ApoAII (in the 
plasma), apoAI, apoB and LpAI (in the plasma and in the “HDL” 
fraction), on the other hand, were quantified by differential electr-
oimmunoassay using ready-to-use plates (SEBIA, France). The 
LpAI: AII concentrations were represented by the difference 
between the LpAI and apoAI levels. The amounts of apoAI and 
LpAI in non-HDL lipoproteins were considered as the differences 





The data were expressed as means (Standard deviation). The 
average concentrations obtained in the two subject groups were 
compared using Student-t test, while percentage were compared 
using the χ
2
-test (chi-square test). Differences were considered as 
significant at P < 0.05. The linear correlation of TG and of apoAI-
containing lipoproteins with other parameters was examined. 
 
 
RESULTS AND DISCUSSION 
 
The mean values (standard deviation) of analysed par-
ameters obtained in two studied populations are shown in 
Table 1. Compared to the control subjects group, the 
obese subject group had a similar average age [30.7 
(7.3) years vs. 32.4 (5.4) years] and fasting plasma 
glucose [4.97 (0.68) mmol/l vs. 4.76 (0.55 mmol/l)] but a 
higher weight excess [38.2 (7.8) vs 5.8 (4.1)%]. In 
addition, average concentrations of p-Chol, HDL-Chol, p-
apoAI, p-apoAII and p-apoB were comparable in the two 
subject groups. However, obese subjects were differ-
entiated through a significant increase of p-TG [1.31 
(0.63) g/l vs. 0.83 (0.18) g/l], HDL-TG (0.23 (0.12) g/l vs 
0.17 (0.09) g/l) and p-LpAI:AII [0.72 (0.16) g/l vs. 0.61 
(0.11 g/l)] and a significant decrease of plasma-apoAI 
percentage associated with LpAI particles [(p-LpAI/ p-
apoAI) x100] [40.77 (8.27) vs. 47.53 (8.65)%] (P < 0.05). 
Besides, a similar distribution of both apoAI and LpAI bet-
ween the HDL and the non-HDL fraction was observed in 
the two subject groups; approximately 90% of apoAI and 
LpAI were associated to the HDL fraction. 
The relation of TG, which was the unique changed lipid 
parameter, to other studied parameters was examined. A 
significant correlation was obtained with HDL-Chol (r = 
0.332, P < 0.05), HDL-TG (r = 0.416, P < 0.05), LpAI:AII 
(r = 0.532, P < 0.001) and LpAI/ LpAI:AII (r = 0.381, P < 
0.05). 
The correlation coefficients of the LpAI, LpAI:AII and 
LpAI/LpAI:AII with studied traditional lipid and lipoprotein 




Table 1. Comparison of control (n-Ob) and obese (Ob) subjects groups. 
  
Parameter n-Ob Ob n-Ob vs Ob 
Age (years) 32.4 (5.4) 30.7 (7.3) ns 
Weight excess (%) 5.8 (4.1) 38.2 (7.8) P < 0.001 
p-Glucose (mmol/ll) 4.76 (0.55) 4.97 (0.68) ns 
p-Chol (g/l) 1.69 (0.39) 1.65 (0.24) ns 
p-TG (g/l) 0.83 (0.18) 1.31 (0.63) P < 0.05 
p-PL (g/l) 1.91 (0.25) 1.79 (0.24) ns 
HDL-Chol (g/l) 0.39 (0.14) 0.36 (0.09) ns 
HDL-TG (g/l) 0.17 (0.09) 0.23 (0.12)  
p-apoAI (g/l) 1.17 (0.12) 1.20 (0.17) ns 
p-apo AII (g/l) 0.25 (0.05) 0.23 (0.04) ns 
p-apoB (g/l) 0.76 (0.18) 0.77 (0.18) ns 
p-LpAI (g/l) 0.56 (0.12) 0.49 (0.10) ns 
p-LpAI:AII (g/l) 0.61 (0.11) 0.72 (0.16) P < 0.05 
p-LpAI/p-apoAI (%) 47.53 (8.65) 40.77 (8.27) P < 0.05 
HDL-apoAI/p-apoAI (%) 88.97 (4.73) 90.35 (2.10) ns 
HDL-LpAI/p-LpAI (%) 89.54 (4.66) 88.70 (2.01) ns 
HDL-TG 0.17 0.23 p< 0.05   
 
Values are expressed as means (standard error). Concentrations and percentages were compared by the t-test and 




Table 2. Linear correlation coefficients of LpAI and LpAI:AII levels and of  LpAI/LpAI:AII ratio with 
lipids and proteins parameters having known value of atherosclerosis marker.   
 
Parameter LpAI LpAI:AII LpAI/LpAI:AII 
TC -0.234 (ns) +0.231 (ns) -0.257 (ns) 
TG -0.176 (ns) +0.532 (***) -0.381 (*) 
HDL-Chol +0.108 (ns) +0.032 (ns) -0.042 (ns) 
apo AI +0.440 (*) +0.635 (***) -0.144 (ns) 
apo B +0.010 (ns) +0.033 (ns) -0.017 (ns) 
 




parameters was examined. Their values and their signifi-
cations are summarized in Table 2. 
The high prevalence of coronary heart disease associated 
with obesity has been attributed, at least partially, to the 
alteration of lipids and lipoprotein profiles. Notably, a 
decrease of HDL-Chol and an increase of both TG and 
LDL were commonly observed in obese populations 
(Bertière et al., 1988; Kissebah et al., 1989; Pascot et al., 
2001; Ho et al., 2002; Franssen et al., 2008; Korsten-
Reck et al., 2008; Chan et al., 2009; Ghandehari et al., 
2009; Taha et al., 2009; Marinou et al., 2010). Among the 
assayed traditional lipid and lipoprotein parameters, only 
the TG concentration was affected (P < 0.05) in our 
obese group. In accordance with our observation, high 
TG levels were often observed in both humans and 
animals. This abnormality could be the results of different 
metabolic dysregulations resulting, notably, from the 
insulin resistance accompanying obesity (Hsiao et al., 
2007; Marinou et al., 2010). The insulin resistance state 
leads to high levels of circulating non-esterified fatty acid 
(NEFA) (due to an excessive adipocytes lipolysis) and an 
increase of hepatic lipogenesis followed by an 
overwhelming hepatic secre-tory capacity (Marinou et al., 
2010). Consequently, the liver could produce an 
abnormal HDL characterized by high TG levels which 
contribute to the observed HDL-TG rise. 
Contrarily to what had been observed in soee studies, 
the high TG levels of our obese subjects group was not 
accompanied by the reduction of HDL levels. Also, TG 
and HDL-Chol showed a positive correlation in our obese 
subjects, while they have been reported to be associated 
negatively in other subject populations (Gou et al., 2005). 
Our study investigates for the first time the profile of 
apoAI-containing lipoproteins which was proposed as a 
determinant factor in the development of the atheroscl-
erosis process (Barkia, 1990). LpAI showed anti-athe-
rogenic properties, while an opposite effect was proposed  





< 0.05), and no change of LpAI. 
Previous studies reported that LpAI:AII are charact-
erized by more TG content than LpAI (Barkia et al., 
1991). This difference could be due, at least in part, to 
the presence of apoAII which could have a potential 
inhibiting effect on the catabolism of TG as suggested by 
the positive relationship between TG and apoAII obser-
ved in mice (Castellani et al., 2008). In our obese 
subjects, plasma apoAII concentration was unchanged. 
So, other causes than the reduction of TG catabolism 
must be considered to explain the enhancement of the 
TG levels in our obese group. 
Also, the enhancement of LpAI:AII particles could 
justify the non rise of apoB concomitantly to the increase 
of TG. However, the possible existence of abnormal 
lipoproteins characterized by a high ratio of TG to apoB 
(TG/apoB), similar to those reported in homozygous stout 
rat (cp/cp) (Dolphin et al., 1987), must be considered. 
The obesity state was associated with an alteration of 
the enzyme activities involved in the lipid and lipoprotein 
metabolism (lipoprotein lipase, cholesteryl ester transfer 
protein, hepatic lipase etc) (Marinou et al., 2010) which 
could lead to the alteration of the lipoprotein profile and 
composition. In agreement with this eventuality, our 
obese subjects seemed to have an abnormal distribution 
of apoAI between the two examined apoAI-containing 
particles. However, no alteration was observed concer-
ning the distribution of both apoAI and apoAI-containing 
lipoproteins between HDL and non-HDL fractions (Table 
1). Also, the correlation of HDL-TG with TG (p < 0.05) 
and with LpAI:AII (p < 0.001) suggests that obese LpAI: 
AII  particles are principally of the HDL type. 
Considering the impact of obesity on the apoAI-containing 
lipoproteins profile, our results cannot be compared with 
others. However, they appear to be concordant with the 
negative correlation existing between TG and HDL2/ 
HDL3 ratio (Takahisa et al., 2005). Indeed, because 
LpAI:AII and LpAI are the major constituents of HDL3 et 
HDL2, respectively (Koren et al., 1987; Barkia, 1990), the 
observed variation of LpAI/ LpAI:AII indicates the 
reduction of HDL2/HDL3. Also, our result confirms the 
positive association of obesity with atherosclerosis 
development. Indeed, the observed increase of relative 
concentration of LpAI:AII which are smaller than LpAI, 
suggests the reduction of HDL size and, then, the 
increase of atherosclerosis risk. Effectively, large HDL 
particles have been associated with a reduction of 
atherosclerosis risk (Pascot et al., 2001). 
Since the LpAI:AII have been shown to be able to 
reduce the cholesterol efflux from cell membrane 
promoted by the LpAI,  an antagonist role to the one of 
LpAI (Barkia et al., 1991),  the observed increase levels of 
LpAI:AII may represent a alteration of reverse cholesterol 
transport leading to an accumulation of cholesterol in non 
hepatic tissues. 
High LpAI:AII levels would act at different manners. 
Firstly, to promote cellular cholesterol efflux, LpAI must 
interact with  a  specific  receptors  of  cellular  membrane  




(apoAI/ apoAII) which link LpAI:II as well (Barkia, 1991). 
The increase of the relative concentration of LpAI:AII 
decreases the LpAI chance to interact with the receptors 
leading to a reduction of cholesterol efflux, and thus to an 
accumulation of cholesterol in non-hepatic tissues. 
Secondly, cholesterol reverse transport depends on the 
lecithin: cholesterol acyltransferase (LCAT) and choles-
teryl ester transfer protein (CETP) which is important in 
the production of cholesterol esters and in their transfer 
from apoAI-containing lipoproteins to apoB-containing 
lipoproteins. Hence, the presence of adequate levels of 
these two activities is necessary for an adequate flow of 
cholesterol from cells to lipoprotein particles. The esta-
blishment of this condition requires the presence of the 
two apoAI-containing lipoproteins at adequate concentra-
tions. Indeed, LpAI and LpAI:AII have different contents 
of LCAT and CETP (Cheung et al., 1986). Consequently, 
because they have an abnormal LpAI/LpAI:AII ratio, our 
obese subjects could have inadequate levels of LCAT 
and CETP activities. In accordance with this suggestion, 
it has been reported that the increase of triglycerides is 
associated with the loss of the normal positive LCAT-
CETP correlation (Tato et al., 1997). Also, the activity of 
LCAT was reported low in individuals with high trigly-
ceride values (Lee et al., 2001). While they have a 
normal level of traditional lipids and lipoproteins para-
meters, our obese group has clearly an altered apoAI-
containing lipoproteins profile. On the basis of literature 
data, the observed change of this profile is favourable to 
the atherogenic processes. 
Our results show that the interest of traditional lipid and 
lipoprotein parameters in the evaluation of the atheroscl-
erosis risk could be limited, and they reinforce the validity 
of LpAI and LpAI:AII concentrations and/or the LpAI/ 
LpAI:AII ratio as markers of atherosclerosis risk which 
seem to have a more effective discrimination value. 
Future studies are necessary to quantify the independent 
contribution of this new parameter to the evaluation of 
coronary heart disease (CHD) risk and the identification 
of the exact anti-atherogenic apoAI-containing lipoproteins.   
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